Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common stock issued @ $4.49	Common stock issued @ $2.26	Common stock issued @ $2.12	Common stock issued @ $1.83	Preferred stock issued at $1,000 per share	Common stock issued @ $5.86	Common stock issued @ $18.95	Common Stock Issued to Galloway	Novartis	Preferred Stock	Preferred Stock Preferred stock issued at $1,000 per share	Common Stock	Common Stock Common stock issued @ $4.49	Common Stock Common stock issued @ $2.26	Common Stock Common stock issued @ $2.12	Common Stock Common stock issued @ $1.83	Common Stock Common stock issued @ $5.86	Common Stock Common stock issued @ $18.95	Common Stock Common Stock Issued to Galloway	Common Stock Novartis	Additional Paid In Capital	Additional Paid In Capital Common stock issued @ $4.49	Additional Paid In Capital Common stock issued @ $2.26	Additional Paid In Capital Common stock issued @ $2.12	Additional Paid In Capital Common stock issued @ $1.83	Additional Paid In Capital Preferred stock issued at $1,000 per share	Additional Paid In Capital Common stock issued @ $5.86	Additional Paid In Capital Common stock issued @ $18.95	Additional Paid In Capital Common Stock Issued to Galloway	Additional Paid In Capital Novartis	Subscriptions Receivable	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance Amount at Sep. 30, 2012	$ 8,808,909												$ 108,354									$ 145,917,968										$ (1,016,000)		$ (134,997,680)	$ (1,203,733)
Beginning Balance Shares at Sep. 30, 2012													13,579,185
Exercise of warrants, Amount	2,054,599												$ 1,183									2,053,416
Exercise of warrants													1,182,451
Stock options exercised, Amount	2,579												$ 1									2,578
Stock options exercised													675
Stock-based compensation	1,536,271																					1,536,271
Subscription payment	16,000																															16,000
Subscription reversal, Amount													$ (2,674)									(997,326)										$ 1,000,000
Subscription reversal													(267,444)
Stock issuances		$ 986,049	$ 3,816,468	$ 3,256,859	$ 25,459,499	$ 9,900,000						$ 10		$ 240	$ 1,825	$ 1,667	$ 14,263						$ 985,809	$ 3,814,643	$ 3,255,192	$ 25,445,236	$ 9,899,990
Stock issuances, Shares												9,900		239,894	1,825,079	1,667,051	14,262,553
Establish and settlements related to derivative liability	1,600,989																					1,600,989
Net loss	(31,703,433)																																	(31,143,289)	(560,144)
Ending Balance Amount at Sep. 30, 2013	25,734,789										$ 10		$ 124,859									193,514,766												(166,140,969)	(1,763,877)
Ending Balance Shares at Sep. 30, 2013											9,900		32,489,444
Exercise of warrants, Amount	10,148,044												$ 2,911									10,145,133
Exercise of warrants													2,911,919
Stock options exercised, Amount	2,730,000												$ 455									2,729,545
Stock options exercised													454,863
Stock-based compensation	5,696,173																					5,696,173
Stock issuances						$ 46,000,000	$ 14,060,112	$ 112,581,559	$ 500,000			$ 46						$ 3,072	$ 6,325	$ 132							$ 45,999,954	$ 14,057,040	$ 112,575,234	$ 499,868
Stock issuances, Shares												46,000						3,071,672	6,325,000	131,579
Establish and settlements related to derivative liability	5,956,079																					5,956,079
Preferred stock converted to common stock, Amount											$ (38)		$ 9,272									(9,234)
Preferred stock converted to common stock, Shares											(37,600)		9,272,459
Deconsolidation of Calando Pharmaceuticals, Inc.	1,303,911																																		1,303,911
Net loss	(58,725,412)																																	(58,630,190)	(95,222)
Ending Balance Amount at Sep. 30, 2014	165,985,255										$ 18		$ 147,026									391,164,558												(224,771,159)	(555,188)
Ending Balance Shares at Sep. 30, 2014											18,300		54,656,936
Exercise of warrants, Amount	401,876												$ 81									401,795
Exercise of warrants													79,828
Stock options exercised, Amount	$ 101,870												$ 29									101,841
Stock options exercised	28,758												28,758
Stock-based compensation	$ 10,232,897																					10,232,897
Exercise of exchange rights, Amount	3,072												$ 5									3,067
Exercise of exchange rights, Shares													5,250
Preferred stock converted to common stock, Amount											$ (2)		$ 1,316									(1,314)
Preferred stock converted to common stock, Shares											(2,648)		1,316,215
Common stock-RSU vesting, Amount	(26,029)												$ 136									(26,165)
Common stock-RSU vesting, Shares													136,307
Stock issuances										$ 25,000,000											$ 3,321										$ 24,996,679
Stock issuances, Shares																					3,321,383
Foreign Currency Translation Adjustments	(136,425)																																$ (136,425)
Net loss	(91,940,882)																																	(91,940,882)
Ending Balance Amount at Sep. 30, 2015	$ 109,621,634										$ 16		$ 151,914									$ 426,873,358											$ (136,425)	$ (316,712,041)	$ (555,188)
Ending Balance Shares at Sep. 30, 2015											15,652		59,544,677